Condition: Ovarian Cancer · Recurrent Epithelial Ovarian Cancer Which Includes Epithelial Ovarian, Fallopian Tube and/or Primary Peritoneal Cancer · Sponsor: PhotonPharma, Inc.
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy Administered in Patients with Recurrent Epithelial Ovarian Cancer
This description comes directly from the study's public registry record.
Beth Crump, RN, BSN · 303-981-1120 · beth.crump@photonpharma.net
Thomas Bogenrieder, MD, Ph.D. · 011 49 2115401040 · thomas.bogenrieder@photonpharma.net
Always discuss trial participation with your own doctor first.
| City of Hope | Duarte, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06366490